针对免疫炎症近端靶点的项目(未明确提及具体产品)
Search documents
Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Seeking Alpha· 2025-09-08 01:58
Company Overview - Annexon Biosciences is focused on classical complement and is pioneering first-in-kind programs targeting immune inflammation across various diseases affecting the body, brain, and eye [3]. Product Development - The company is developing a program for Guillain-Barré syndrome, which is the first and only program in this space in the last 50 years, demonstrating landmark unprecedented data in improving patient outcomes [4].